U.S. Markets closed

Histogen Inc. (HSTO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8108+0.0199 (+2.52%)
At close: 4:00PM EDT
0.8007 -0.01 (-1.25%)
After hours: 05:36PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7909
Open0.7800
Bid0.8010 x 1400
Ask0.8298 x 1300
Day's Range0.7800 - 0.8200
52 Week Range0.7400 - 2.4100
Volume210,964
Avg. Volume900,581
Market Cap28.982M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.70
  • GlobeNewswire

    Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. Presentation DetailsThe presentation will be available

  • GlobeNewswire

    Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

    Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression Emricasan Found to Have Statistically Significant Improvements in Clinically Relevant Hematological and Immune Markers Which May Lead to Potential Clinical Benefits in COVID-19 Patients SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) and its partner Amerimmune, LLC today announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to a

  • GlobeNewswire

    Histogen Reports Second Quarter 2021 Earnings and Provides Business Update

    Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates Initiated Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee HST 004 Selected as Product Candidate for Spinal Disc Repair with IND Enabling Activities Underway Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on d